证券代码：002432 证券简称：九安医疗 公告编号：2025-061 一、以6票同意、0票反对、0票弃权的表决结果，审议通过了《关于变更部 分回购股份用途并注销的议案》 为积极维护公司市值，增强上市公司股东回报，结合公司实际情况，董事会 同意将 2023 年度回购股份实施完毕后，存放于回购专用账户中原计划用于维护 公司价值及股东权益，并可通过集中竞价交易方式减持的 9,771,882 股股份用途 变更为"用于注销并减少公司注册资本"。 该事项尚需股东大会审议通过方可实施。公司董事会提请股东大会授权公司 管理层办理股份注销等相关手续。 具 体 内 容 详 见 公 司 同 日 刊 登 于 《 证 券 时 报 》 及 巨 潮 资 讯 网 （http://www.cninfo.com.cn）的《关于变更部分回购股份用途并注销暨减少注册 资本的公告》（公告编号：2025-063）。 天津九安医疗电子股份有限公司 第六届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司(以下简称"公司"或"本公司")于2025年9 ...

Group 1 - The issuance of the 2025 first phase technology innovation bond by Tianjin Jiuan Medical Electronics Co., Ltd. marks a significant milestone as it is the first technology innovation bond for private technology enterprises in Tianjin, with a total issuance scale of 1.05 billion yuan [1] - The bond issuance is a key initiative by Industrial Bank Tianjin Branch to support the development of private technology enterprises, aligning with the central financial work conference's spirit and promoting financial resources towards "early, small, long-term, and hard technology" sectors [1][3] - The funds raised from the bond will be primarily allocated to upgrading smart medical devices and building a digital platform for chronic disease management, enhancing the company's technological leadership in the industry [2] Group 2 - Jiuan Medical has established a strong foundation for the bond issuance through its commitment to technological innovation, with a dedicated R&D team and significant investment in research, resulting in multiple national patents and industry awards [2] - The company's iHealth series of smart medical devices integrates mobile internet technology with precise detection functions, covering various health monitoring scenarios and achieving a market presence in over 100 countries [2] - The company has developed an innovative "O+O" model for diabetes management, providing comprehensive services from screening to long-term health management, having served over 500,000 chronic disease patients [2]

Core Insights - Beijing Qiji Chuangtan Phase II Venture Capital Center (Limited Partnership) has undergone a business change, adding Xiaomi's subsidiary fund Huanxing Venture Capital Co., Ltd. and Jiuan Medical (002432) as shareholders [1] Group 1 - The company was established in 2022 with a registered capital of 906 million yuan [1] - The business scope includes private equity fund activities such as equity investment, investment management, and asset management [1]

Group 1 - Konomei (Beijing) Technology Co., Ltd. has completed several million yuan A+ round financing, led by Jiuan Medical, to accelerate commercialization and continue independent research and innovation [1] - The company, founded in 2019, focuses on the independent research and industrialization of ultra-high performance liquid chromatography (UHPLC) technology, with the core founding team having an average of nearly 20 years of experience in the life science instrument field [1] - As of April 2025, Konomei has applied for over 30 patents and software copyrights, including 6 invention patents and 14 utility model patents, along with multiple proprietary technologies [1] Group 2 - Jiuan Medical's chairman, Liu Yi, emphasizes the company's commitment to discovering and partnering with practical enterprises that can address industry pain points and lead industrial upgrades [2] - Jiuan Medical focuses on two core opportunities: deepening independent research around the "Stanford model" to activate the "engineer dividend" and seizing the wave of domestic scientific instrument production and policy support to promote import substitution in the global market [2] - Konomei's breakthroughs in the ultra-high performance liquid chromatography field have disrupted China's long-standing reliance on imports in the high-end market of this sector [2]

Core Insights - Konomai (Beijing) Technology Co., Ltd. has completed several million yuan in A+ round financing, led by Jiuan Medical, to accelerate commercialization and continue independent research and innovation [3] - The Chinese analytical instrument market heavily relies on imports, with annual import value around $100 billion, particularly in liquid chromatography as the leading product [3] - Konomai, established in 2019, focuses on the independent research and industrialization of ultra-high-performance liquid chromatography (UHPLC) technology, with a core founding team averaging nearly 20 years of experience in life science instruments [3][4] - The company has achieved a 95% localization rate for product components as of 2022, with a full series of UHPLC products developed [4] Company Performance - Since the start of its commercialization in 2023, Konomai has maintained an annual sales growth rate exceeding 50%, with overseas market growth surpassing 80% [5] - The company has expanded its customer base to hundreds across over 20 countries and regions, covering various fields such as drug analysis, biosynthesis, academic research, food safety, and environmental protection [5] Investment Perspective - Jiuan Medical's chairman, Liu Yi, emphasizes the focus on practical enterprises that can address industry pain points and lead industrial upgrades, highlighting Konomai's role in breaking the long-standing reliance on imports in the high-end market of ultra-high-performance liquid chromatography [6]

Core Viewpoint - The article highlights the significant advancements and growth of Konomai (Beijing) Technology Co., Ltd. in the high-end scientific instrument sector, particularly in the field of ultra-high-performance liquid chromatography (UHPLC), emphasizing its role in the domestic market's shift towards self-sufficiency and reduced reliance on imports [2][5]. Group 1: Company Overview - Konomai has completed a multi-million A+ round of financing led by Jiuan Medical, with funds aimed at accelerating commercialization and continuous innovation in independent research and development [2]. - Founded in 2019, Konomai focuses on the independent research and industrialization of UHPLC technology, with its core founding team averaging nearly 20 years of experience in the life science instrument field [2]. - The company has applied for over 30 patents and software copyrights, including 6 invention patents and 14 utility model patents, as of April 2025 [2]. Group 2: Product and Market Position - Konomai has achieved a 95% localization rate for its product components, significantly contributing to the reduction of procurement costs and enhancing analysis efficiency for clients [3]. - The company has launched a full series of UHPLC products, including automated IVD two-dimensional liquid chromatography systems and intelligent chromatography data management systems [2]. - Since initiating its commercialization strategy in 2023, Konomai has experienced a sales growth rate exceeding 50% annually, with international market growth surpassing 80% [3][4]. Group 3: Investment Perspective - Jiuan Medical's chairman, Liu Yi, emphasizes the importance of collaborating with practical enterprises that can address industry pain points and lead industrial upgrades, focusing on self-research and the domestic scientific instrument market [5]. - Konomai's advancements in the UHPLC sector are seen as pivotal in breaking the long-standing reliance on imports in China's high-end market [5].

Group 1 - The core viewpoint of the news is that Jiuan Medical has experienced fluctuations in its stock performance and financing activities, indicating a high level of trading activity and investor interest [1][2]. - On August 29, Jiuan Medical's stock price decreased by 0.20%, with a trading volume of 351 million yuan. The net financing buy was negative at -29.59 million yuan, indicating more selling than buying in the financing market [1]. - As of August 29, the total balance of margin trading for Jiuan Medical was 1.266 billion yuan, with a financing balance of 1.259 billion yuan, representing 6.72% of its market capitalization, which is above the 90th percentile of the past year [1]. Group 2 - As of August 10, the number of Jiuan Medical's shareholders increased by 2.24% to 73,000, while the average number of circulating shares per person decreased by 2.19% to 6,491 shares [2]. - For the first half of 2025, Jiuan Medical reported a revenue of 765 million yuan, a year-on-year decrease of 43.35%, while the net profit attributable to shareholders increased by 52.91% to 920 million yuan [2]. - The company has distributed a total of 1.794 billion yuan in dividends since its A-share listing, with 1.39 billion yuan distributed in the last three years [2].

Group 1 - CITIC Prudential Fund recently conducted research on two listed companies: Jiuan Medical and Nengke Technology [1] - Jiuan Medical's new product for 2024 utilizes colloidal gold immunochromatography technology for qualitative detection of influenza A, B, and Covid viruses, and is now a common home virus screening tool in the US market [1] - Nengke Technology reported that revenue growth from AI products and services is supported by external environment and internal strategies, with a clear trend towards smart manufacturing upgrades [1] Group 2 - Nengke Technology's gross margin improvement is attributed to business and product structure adjustments, focusing on high-margin sectors while reducing inefficient operations [1] - The company is in the early stages of vertical application development, with significant R&D investment and a long development cycle, aiming to enhance market share through continuous innovation [1] - CITIC Prudential Fund has an asset management scale of 162.93 billion yuan, ranking 44th among 210 funds, with a recent top-performing fund showing a 96.13% growth over the past year [2]

Group 1 - The core viewpoint of the article highlights that Zhongjia Fund has conducted research on Jiuan Medical (002432), which is set to launch a new product in 2024 that utilizes colloidal gold immunochromatography technology for virus detection [1] - Jiuan Medical's new product can qualitatively detect and differentiate between influenza A, influenza B, and Covid viruses, and has become a regular home virus screening tool in the US market, widely sold through channels like Amazon, CVS, and Walmart [1] - Zhongjia Fund, established in 2013, currently manages a total asset scale of 141.193 billion yuan, ranking 49th out of 210 in the public fund management sector [1] Group 2 - The fund's non-monetary public fund asset management scale is 124.22 billion yuan, ranking 42nd out of 210 [1] - Zhongjia Fund manages 135 public funds, ranking 60th out of 210, with 19 fund managers, ranking 72nd out of 210 [1] - The best-performing public fund product in the past year is the Zhongjia Technology Innovation Mixed Fund A, which has seen a growth of 150.68%, with the latest unit net value at 1.82 [1]

Group 1 - The core viewpoint of the article highlights the strong financial performance of Jiuan Medical in the first half of 2025, with a revenue of 765 million yuan and a net profit of 920 million yuan, marking a year-on-year growth of 52.91% [1] - The iHealth product series significantly contributed to the company's revenue, generating approximately 601 million yuan, showcasing its market competitiveness and profitability [1] - The sales of the company's reagent kits are performing well, particularly on the Amazon platform, where they rank as Best Seller in their category despite higher prices compared to similar products [1] Group 2 - In the field of smart hearing aids, the company is developing a new AI smart hearing aid that utilizes a mobile hearing calculation architecture and AI neural network algorithms to enhance user experience [1] - The diabetes care business generated revenue of 50.26 million yuan in the first half of 2025, with the new "O+O" care model being promoted in approximately 50 cities and 424 hospitals, serving around 366,000 patients [1] - The asset management business is primarily conducted through Jiuan Hong Kong, with a diversified asset portfolio comprising 59.2% fixed income, 26.2% public market equities, 12.6% private equity, and 2.0% hedge funds as of mid-2025 [2] Group 3 - The company has invested in several high-quality venture capital funds, focusing on next-generation AI technologies and their applications, indicating a forward-looking approach in the tech innovation sector [2] - Jiuan Medical is involved in a 5 billion yuan investment in the Tiankai Jiuan Haihe Haitang Science and Technology Innovation Fund, which aims to cover the entire industrial chain in AI through investments in sub-funds [2] - Currently, 16 sub-funds have been approved, with the science and technology innovation fund contributing 1.69 billion yuan, expected to create a fund pool of 7.2 billion yuan [2]